The phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq (atezolizumab) showed non-inferior levels of Tecentriq in the blood, when injected subcutaneously, compared with intravenous infusion.
Tecentriq is sponsored by Genentech.
The study included cancer immunotherapy-naïve patients with locally advanced or metastatic NSCLC for whom prior platinum therapy has failed.
The safety profile of the subcutaneous formulation was consistent with that of IV Tecentriq.
Subcutaneous administration would reduce the time patients spend receiving treatment from 30-60 minutes with IV infusion to only 3-8 minutes.
Genentech will share detailed findings of the IMscin001 study at an upcoming medical meeting and submit them for regulatory approval to health authorities globally, including FDA and European Medicines Agency.
